|
gptkbp:instanceOf
|
gptkb:drug
gptkb:monoclonal_antibody
|
|
gptkbp:administeredBy
|
subcutaneous injection
|
|
gptkbp:approvedBy
|
gptkb:United_States
gptkb:FDA
2017
|
|
gptkbp:ATCCode
|
gptkb:D11AH05
|
|
gptkbp:CASNumber
|
gptkb:1190264-60-8
|
|
gptkbp:contraindication
|
hypersensitivity to dupilumab
|
|
gptkbp:developedBy
|
gptkb:Sanofi
gptkb:Regeneron_Pharmaceuticals
|
|
gptkbp:form
|
pre-filled pen
pre-filled syringe
|
|
gptkbp:halfLife
|
~14-16 days
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Dupilumab
|
|
gptkbp:indication
|
gptkb:prurigo_nodularis
chronic rhinosinusitis with nasal polyposis
eosinophilic esophagitis
moderate-to-severe asthma
moderate-to-severe atopic dermatitis
|
|
gptkbp:KEGGID
|
D10560
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:marketedAs
|
gptkb:Dupixent
|
|
gptkbp:mechanismOfAction
|
blocks IL-4 and IL-13 signaling
|
|
gptkbp:molecularWeight
|
147 kDa
|
|
gptkbp:notableCase
|
gptkb:CHRONOS
gptkb:LIBERTY_ASTHMA_QUEST
gptkb:SOLO_1
gptkb:SOLO_2
|
|
gptkbp:patent
|
gptkb:Sanofi
gptkb:Regeneron_Pharmaceuticals
|
|
gptkbp:pregnancyCategory
|
unknown
|
|
gptkbp:prescribes
|
adolescents
adults
children (certain indications)
|
|
gptkbp:prescriptionStatus
|
Rx only
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL3989989
gptkb:DB12161
|
|
gptkbp:routeOfAdministration
|
subcutaneous
|
|
gptkbp:sideEffect
|
conjunctivitis
injection site reactions
eye inflammation
oral herpes
|
|
gptkbp:target
|
gptkb:interleukin-4_receptor_alpha
interleukin-13 pathway
|
|
gptkbp:UNII
|
6J3J1TKW2W
|
|
gptkbp:usedFor
|
gptkb:prurigo_nodularis
gptkb:atopic_dermatitis
asthma
chronic rhinosinusitis with nasal polyposis
eosinophilic esophagitis
|
|
gptkbp:bfsParent
|
gptkb:IL4
|
|
gptkbp:bfsLayer
|
6
|